PHARMACY

HDMA re-elects board leaders, adds new members

BY David Salazar

ARLINGTON, Va. — The Healthcare Distribution Management Association announced the members and leaders of its board of directors from the organization’s annual meting. 

Dakota Drug president and CEO Ted M. Scherr was re-elected to be chairman of the board, and Cardinal Health’s Pharmaceutical Segment CEO Jon Giacomin won another term as the board’s vice chairman.

HDMA also announced the newest members of its board of directors — Morris & Dickson Co. president Paul Dickson; Louisiana Wholesale Drug president and CEO Chad Gielen; EVP and president of AmerisourceBergen Drug Corp. Bob Mauch; and Charles “Chip” Phillips, president of Anda.

“HDMA is pleased to welcome back Ted and Jon, as well as all our new Directors, as we continue the important business of ensuring the efficiency and safety of the healthcare supply chain for all Americans.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Lopid generic from Aurobindo

BY DSN STAFF

Dayton, N.J. — Aurobindo Pharma Limited announced Monday that it had received approval from the Food and Drug Administration for its generic of Pfizer’s Lopod (gemfibrozil) tablets in 600-mg dosage strength.

The drug is intended to treat high cholesterol alongside diet and exercise. Brand sales for Lopid in the U.S. were about $35.1 million for the twelve months ended July 2015, according to IMS Health. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Sprout announces availability of Addyi REMS training

BY David Salazar

RALEIGH, N.C. — Sprout Pharmaceuticals recently announced that pharmacists and providers can now enroll Risk Evaluaiton and Mitigation Strategy training to become certified to prescribe or dispense Addyi (filbanserin), the recently approved drug that treats hypoactive sexual desire disorder in premenopausal women. 
 
“We are committed to patient safety first and foremost, and as such, our priority is to educate prescribers and pharmacies about Addyi leading up to its availability,” Sprout CEO Cindy Whitehead said. “The millions of women who suffer from HSDD have been awaiting a treatment option for years, and we look forward to working with healthcare providers and pharmacies to provide them with education on Addyi.”
 
The REMS materials can be accessed from Addyi.com and prescriber and pharmacists have to review and complete a knowledge assessment. The program is designed to reduce the risk of syncope and hypertension that can occur when Addyi interacts with alcohol. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?